---
title: "\"Performance\" MIN XIN HOLD's annual net profit is 120 million yuan, an increase of 36.4%, with a final dividend of 8 cents"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/280677582.md"
description: "MIN XIN HOLD announced its 2025 annual performance, with operating revenue of 279 million yuan, an increase of 6% year-on-year. It recorded a net profit of 120 million yuan, a growth of 36.4%, with earnings per share of 20.03 cents. The final dividend is 8 cents"
datetime: "2026-03-26T19:05:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280677582.md)
  - [en](https://longbridge.com/en/news/280677582.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280677582.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/280677582.md) | [English](https://longbridge.com/en/news/280677582.md)


# "Performance" MIN XIN HOLD's annual net profit is 120 million yuan, an increase of 36.4%, with a final dividend of 8 cents

MIN XIN HOLD (00222.HK) announced its 2025 annual performance, with operating revenue of HKD 279 million, an increase of 6% year-on-year. It recorded a net profit of HKD 120 million, a growth of 36.4%, with earnings per share of HKD 0.2003. A final dividend of HKD 0.08 was declared

### 相關股票

- [MIN XIN HOLD (00222.HK)](https://longbridge.com/zh-HK/quote/00222.HK.md)

## 相關資訊與研究

- [China's detentions of Panama-flagged vessels raise concerns, Rubio says](https://longbridge.com/zh-HK/news/281541796.md)
- [UniCredit - as of YE25 group MREL equal to 30.6% of RWA, 10% of LRE](https://longbridge.com/zh-HK/news/281399909.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/zh-HK/news/281325910.md)
- [MINISO Extends Hong Kong Share Buybacks as 2025 Results Filed](https://longbridge.com/zh-HK/news/281398103.md)
- [CICC Sticks to Its Buy Rating for C&D International Investment Group Ltd. (1908)](https://longbridge.com/zh-HK/news/280899096.md)